Participants
- Diana Thiara, MD, DABOM, UCSF Health (moderator)
- Michelle Guy, MD, UCSF Health
- Mackenzie Clark, PharmD, UCSF Health
- Lisa Kroon, PharmD, CDCES, FAPhA, UCSF Health
Pharmacy teams can shorten the time of Medicare GLP-1 Bridge approvals, but 2027 approval windows may leave patients without titration check-ins.
Centralizing Medicare GLP-1 Bridge prior authorization (PA) requests within a health system pharmacy team produced PA responses in about 1 hour, but approvals that stay valid through 2027 remove the clinical check-in that PAs typically prompt. Pharmacists are using refill reviews to fill that gap, prompting dose titration and follow-up. The practices were discussed at The American Journal of Managed Care®’s Population Health Roundtable in San Francisco. Some participants in this discussion asked their comments not to be attributed directly to them, so their comments are attributed generally.
The discussion was moderated by Diana Thiara, MD, of University of California, San Francisco (UCSF) Health, who led 6 colleagues from multiple disciplines through discussions of obesity care ownership, operational barriers, and comorbidities. The Bridge demonstration runs from July 1, 2026, through December 31, 2027, and offers eligible Part D beneficiaries select glucagon-like peptide-1 (GLP-1) receptor agonists for a fixed $50 copay per 30-day supply.
Prescribing for GLP-1s is spreading beyond weight management clinics, said Mackenzie Clark, PharmD, of UCSF Health, who noted that dermatology, rheumatology, and gastroenterology now start these agents. Clark described 3 forces that shift ownership: patients' trust in a particular clinician, which prescriber has the most success getting coverage (such as for the sleep apnea indication), and which clinic has the resources to support therapy.
Thiara said UCSF Health lacks executive-level support to coordinate obesity care. "I don't think the system is good at triaging patients to the correct subspecialist," she said, adding that a switch to a central contact center has meant urgent transplant candidates are not being scheduled within the 1-month target. A Patient-Centered Outcomes Research Institute grant is funding a 12-week intensive lifestyle program with group visits for primary care patients with obesity, she said.
Capacity is the other constraint. Michelle Guy, MD, of UCSF Health, noted that a clinician seeing 4 new patients weekly must follow each for about a year and a half. She said systems should model patient volumes and dropout rates and hire 1 or 2 weight management clinicians annually. Access also favors patients with time.
"Oftentimes the patients with the most wherewithal and resources are the ones that get in the door first," Guy said.
Clark, who manages the health system's central medication access center, said PA volume rose 60% in July after the Bridge program began. Pharmacies often cannot adjudicate Bridge claims, and a PA cannot be filed until they do.
"I think the access point on this is [to] send everything to our internal pharmacies because pharmacies don't know how to bill it," Clark said. Once requests were routed internally, her team received PA responses in about 1 hour.
Clark flagged 2 pitfalls. Any prior Medicare fill, including an incidental transition fill that Part D never covered, triggers a hard stop with no appeals process because the pilot sits outside normal Part D rules. In 1 clinic, standardized PA documentation reduced GLP-1 prescribing because prescribers had to confirm patients met criteria.
Cost and patient expectations complicate access. Clark said many patients were willing to pay $50 because the alternative was $200 to $400 for the drug, but the copay does not count toward deductibles or out-of-pocket limits, and dual-eligible patients struggle most. "I would agree, $50 sounds a good delta, but it's still too costly," said a participating pharmacist.
Patients also arrive with treatment preferences set, Thiara said, citing direct-to-consumer telehealth marketing that invites them to pick their drug and dose.
"There's no other area of medicine where the patient knocks on the door with their mind made up so well," she said.
Because Bridge PAs remain valid through December 31, 2027, unless the GLP-1 changes, the usual reauthorization checkpoint disappears. "These patients are going to be on it for a year and a half with no process where the PA actually causes you to check in on the patient," Clark said. Without a prescriber process, she said, patients could stay on starting doses or lose excess weight unmonitored.
Clark described refills as the best stopgap. Pharmacists now review primary care refills, titrating doses and confirming follow-up appointments, and she wants prescribers to set refill counts that align with planned check-ins.
Guy's main takeaway was collaboration within a patient-first, patient-centered model. Clark pointed to quick wins, such as standardized provider and patient education in the chart, and said pharmacy roadshows and tip-of-the-month messages have been effective.
“I do think people are listening when you can kind of give them that type [of education]…” Clark said. “What education can we give to patients and [what] modules are out there that we can kind of use across the system and not recreate [the work]?”






